150190-99-1 Usage
General Description
1,2-Benzenediol, 4-bromo-3-fluoro- (9CI) is a chemical compound that is also known as 4-Bromo-3-fluorocatechol. It is a halogenated derivative of catechol, which is commonly found in fruits and vegetables. 1,2-Benzenediol, 4-bromo-3-fluoro- (9CI) is used in the pharmaceutical industry as a building block for the synthesis of various drugs, particularly in the development of anticancer and antiviral agents. 1,2-Benzenediol, 4-bromo-3-fluoro- (9CI) is also utilized in research and development as a reagent in organic synthesis, and its properties and structure make it an important tool for studying the structure-activity relationships of catechol derivatives. Overall, this chemical compound has important applications in pharmaceuticals and research, and its unique structure makes it a valuable tool in drug discovery and development.
Check Digit Verification of cas no
The CAS Registry Mumber 150190-99-1 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,5,0,1,9 and 0 respectively; the second part has 2 digits, 9 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 150190-99:
(8*1)+(7*5)+(6*0)+(5*1)+(4*9)+(3*0)+(2*9)+(1*9)=111
111 % 10 = 1
So 150190-99-1 is a valid CAS Registry Number.
150190-99-1Relevant articles and documents
CYANOCYCLOPROPYLCARBOXAMIDES AS CATHEPSIN INHIBITORS
-
Page/Page column 268, (2009/03/07)
The present invention relates to compounds of formula (I) for treating diseases associated with cysteine protease activity. The compounds are reversible inhibitors of cysteine proteases, including cathepsins B, K, C, F, H, L, O, S, W and X. Of particular interest are diseases associated with Cathepsin K.
Cephalosporin derivatives
-
, (2008/06/13)
Cephalosporin derivatives have the formula STR1 wherein Z1, Z2, X, Y, P, Q, m, n and p are as defined in the following text. Also described are the readily hydrolyzable esters and pharmaceutically compatible salts of these compounds, and hydrates of compounds of formula I, their esters and salts. Processes are provided for manufacture and pharmaceutical preparations which contain these compounds. Intermediates from the manufacture of these compounds are described, as is the use of the compounds in the control of illnesses and for the manufacture of the aforementioned preparations.
